The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology ...

VANCOUVER, BC / ACCESS Newswire / November 18, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it is initi ...

The company, which had no revenue last year and $5.1 million in sales for the first nine months of this year with widening ...

Rakovina Therapeutics Inc. ('Rakovina” or the 'Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that its ...

A Western-led interdisciplinary research team is using artificial intelligence (AI) to target a potentially harmful enzyme found in the human body ...

Scientists accidentally discovered how an old blood pressure drug hydralazine could fight aggressive brain cancer by ...

DeepTarget is a computational tool that integrates large-scale drug screens with omics data to predict mechanisms of cancer cell killing.

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.

A Penn-led team has revealed how hydralazine, one of the world's oldest blood pressure drugs and a mainstay treatment for ...

For rare diseases, AI-driven repurposing fills a critical gap. With more than 7000 rare diseases and only a small percentage ...